These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 957902)

  • 41. L-Dopa and imipramine: biochemical and behavioral interaction.
    Friedman E; Gershon S
    Eur J Pharmacol; 1972 May; 18(2):183-8. PubMed ID: 5037381
    [No Abstract]   [Full Text] [Related]  

  • 42. alpha-difluoromethyl DOPA, a new enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase.
    Palfreyman MG; Danzin C; Bey P; Jung MJ; Ribereau-Gayon G; Aubry M; Vevert JP; Sjoerdsma A
    J Neurochem; 1978 Oct; 31(4):927-32. PubMed ID: 308998
    [No Abstract]   [Full Text] [Related]  

  • 43. Decarboxylase inhibitors.
    Bartholini G; Pletscher A
    Pharmacol Ther B; 1975; 1(3):407-21. PubMed ID: 772711
    [No Abstract]   [Full Text] [Related]  

  • 44. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)].
    Geissbühler F; Widmer J
    J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of L-dopa with and without decarboxylase inhibitor on growth hormone secretion in children with short stature.
    Fevang FO; Stoa RF; Thorsen T; Aarskog D
    Acta Paediatr Scand; 1977 Jan; 66(1):81-4. PubMed ID: 831384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol].
    Rochiccioli P; Enjaume P; Dutau G; Ribot C; Augier D
    Arch Fr Pediatr; 1976 Jan; 33(1):55-66. PubMed ID: 985031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
    Lieberman A; Estey E; Gopinathan G; Ohashi T; Sauter A; Goldstein M
    Neurology; 1978 Sep; 28(9 Pt 1):964-8. PubMed ID: 567768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Skeletal changes induced by dopa decarboxylase inhibitor in rats.
    Tanaka C; Tanaka S; Itokawa Y; Takaori S
    Jpn J Pharmacol; 1973 Feb; 23(1):123-5. PubMed ID: 4541614
    [No Abstract]   [Full Text] [Related]  

  • 49. Site of action of methyldopa in lowering the blood pressure in man.
    Kersting F; Reid JL; Dollery CT
    Clin Exp Pharmacol Physiol Suppl; 1978; 4():11-5. PubMed ID: 277299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compulsive gnawing.
    Ernst AM
    Pharmacol Ther B; 1976; 2(1):173-84. PubMed ID: 772718
    [No Abstract]   [Full Text] [Related]  

  • 51. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM; Scheline RR
    J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
    [No Abstract]   [Full Text] [Related]  

  • 52. Inhibition of catechol-O-methyl transferase by L-dopa and decarboxylase inhibitors.
    Baldessarini RJ
    J Pharm Pharmacol; 1972 Jan; 24(1):78-80. PubMed ID: 4401326
    [No Abstract]   [Full Text] [Related]  

  • 53. Nicotinic acid or N-methyl nicotinamide prolongs elevated brain dopa and dopamine in L-dopa treatment.
    Black MJ; Brandt RB
    Biochem Med Metab Biol; 1986 Oct; 36(2):244-51. PubMed ID: 2946308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Central dopamine receptors regulate blood eosinophilia in the rat.
    Podolec Z; Vetulani J; Bednarczyk B; Szczeklik A
    Allergy; 1979 Apr; 34(2):103-10. PubMed ID: 474944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood-brain barrier to carbidopa (MK-486) and Ro 4-4602, peripheral dopa decarboxylase inhibitors.
    Clark WG; Oldendorf WH; Dewherst WG
    J Pharm Pharmacol; 1973 May; 25(5):416-8. PubMed ID: 4146401
    [No Abstract]   [Full Text] [Related]  

  • 56. Pyridoxal 5'-phosphate levels in brain after treatments which impair cerebral glucose metabolism.
    Wong KL; Tyce GM
    Neurochem Res; 1979 Dec; 4(6):821-6. PubMed ID: 44547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous l-DOPA plus carbidopa in depressed patients: average evoked response, learning, and behavioral changes.
    Henry GM; Buchsbaum M; Murphy DL
    Psychosom Med; 1976; 38(2):95-105. PubMed ID: 1273240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of thymoleptics on behaviour associated with changes in brain dopamine. I. Potentiation of dopa-induced gnawing of mice.
    Molander L; Randrup A
    Psychopharmacologia; 1976 Feb; 45(3):261-5. PubMed ID: 943120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The aromatic amino acid decarboxylase inhibitor, NSD-1015, increases release of dopamine: response characteristics.
    Dluzen D; Reddy A; McDermott J
    Neuropharmacology; 1992 Dec; 31(12):1223-9. PubMed ID: 1470299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [HGH secretion after oral application of L-dopa and L-carbidopa (author's transl)].
    Schönberger W; Ziegler R; Brodt B; Grimm W
    Eur J Pediatr; 1976 Jun; 122(3):195-200. PubMed ID: 1278188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.